DermTech
La Jolla
About DermTech
DermTech develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. The Company’s assays can analyze multiple gene targets to assess their level of RNA expression. The Company anticipates providing these assays through a CLIA certified laboratory located in San Diego. The Company will initially offer an assay for pigmented skin lesions sampled using an adhesive tape collection method. The Company has identified gene targets differentially expressed in melanoma samples (British Journal of Dermatology, April 2011). This assay can assess RNA expression consistent with melanoma with very high sensitivity (>95%) and specificity (>70%).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $259.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2021)
- Ticker: nasdaq:DMTK
- Website: dermtech.com
- Phone: +1 858 450 4222
Industries & Categories
Beauty, Biotechnology, Genetics, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/dermtech-68657 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.